Acute promyelocytic leukaemia is a rare but serious form of blood cancer that demands swift action. Thanks to groundbreaking advances in treatment combining targeted therapies with carefully coordinated care, this once rapidly fatal disease has become one of the most curable forms of leukaemia, offering hope and long-term remission to most patients.

How Treatment Has Transformed Lives

The journey of treating acute promyelocytic leukaemia has been nothing short of remarkable. Just decades ago, this condition was considered one of the deadliest forms of blood cancer, with patients often surviving less than a week without treatment^[2]. The disease moved quickly, causing severe bleeding that could not be controlled, leaving doctors with few options and families with little hope.

Today, the story is dramatically different. Modern treatment can cure most cases of this condition, with complete remission rates approaching 100% when proper therapy is started promptly^[2]. This transformation began in the mid-1980s when researchers discovered that a vitamin A-derived medication could help immature blood cells mature properly. Later additions of other targeted drugs have turned acute promyelocytic leukaemia into what many specialists now consider a highly curable malignancy^[1].

The primary goals of treatment are to quickly stop the dangerous bleeding that threatens patients’ lives, eliminate the abnormal cells causing the disease, maintain long-term remission, and ultimately cure the condition. Treatment must begin immediately—sometimes even before doctors have confirmed the diagnosis through laboratory tests—because delays can be life-threatening. The speed at which treatment starts can make the difference between life and death in the early days of this illness.

Treatment plans are carefully tailored to each patient based on several factors. Doctors consider the patient’s white blood cell count (the number of infection-fighting cells in the blood), overall health status, heart function, and whether the disease has returned after previous treatment. These factors help the medical team decide which combination of therapies will work best and be safest for each individual.

Standard Treatment: The Foundation of Care

Standard treatment for acute promyelocytic leukaemia follows a structured approach divided into three distinct phases: induction, consolidation, and maintenance. Each phase has a specific purpose and uses different combinations of medications to achieve the best possible outcome^[10].

The first phase, called induction therapy, aims to bring the disease into complete remission. This means eliminating all detectable leukaemia cells from the blood and bone marrow. The cornerstone of induction therapy is a medication called all-trans retinoic acid, commonly known as ATRA. This drug is derived from vitamin A and works in a unique way—instead of killing cancer cells, it helps the immature abnormal white blood cells mature and develop normally^[11].

ATRA is typically given alongside other medications to achieve the best results. For patients with lower white blood cell counts (considered low-risk disease), ATRA may be combined with arsenic trioxide, a substance that has proven remarkably effective in treating this specific type of leukaemia^[10]. For patients with higher white blood cell counts (high-risk disease), doctors often add chemotherapy drugs such as idarubicin or daunorubicin. These medications work by stopping cancer cells from multiplying.

In some cases, doctors may also use a targeted therapy drug called gemtuzumab ozogamicin (Mylotarg). This medication attaches to specific proteins on the surface of leukaemia cells and delivers a cancer-killing substance directly to them^[10]. The induction phase typically lasts about one to two months, and patients are monitored closely during this time through blood tests and bone marrow examinations.

Once remission is achieved, the second phase begins. Consolidation therapy is designed to eliminate any remaining leukaemia cells that may be hiding in the body but cannot be detected by standard tests. This phase is crucial because even a small number of remaining abnormal cells could cause the disease to return. Consolidation treatment usually involves the same drugs used during induction, given in cycles with rest periods in between to allow the body to recover^[10].

The final phase, maintenance therapy, involves taking lower doses of medication for an extended period, often lasting one to two years. This phase helps prevent the disease from coming back. Maintenance treatment typically includes ATRA given in cycles, sometimes combined with chemotherapy medications^[10]. While this may seem like a long time to be on treatment, it significantly reduces the chance of relapse and improves long-term survival.

Throughout all phases of treatment, doctors carefully monitor patients for potential side effects and complications. One of the most concerning early complications is differentiation syndrome, which can occur when ATRA or arsenic trioxide causes too many leukaemia cells to mature at once. Symptoms may include fever, difficulty breathing, weight gain, and fluid accumulation around the lungs or heart. When caught early, this condition can be treated effectively with steroids and sometimes requires temporarily stopping the ATRA or arsenic trioxide^[15].

Another potential complication involves the heart. Arsenic trioxide can affect the heart’s electrical system, causing a condition called prolonged QT interval, which can lead to dangerous heart rhythm problems. For this reason, patients receiving this medication undergo regular electrocardiograms (heart rhythm tests) to monitor for any changes^[15].

During the early days of treatment, managing bleeding and clotting problems is essential. Patients may need transfusions of platelets, which help blood clot, as well as other blood products like fresh frozen plasma or cryoprecipitate to replace missing clotting factors^[18]. These supportive measures continue until the treatment starts working and the bone marrow begins producing normal blood cells again.

Common side effects from chemotherapy may include nausea, vomiting, hair loss, mouth sores, and increased risk of infection due to low white blood cell counts. ATRA can cause dry skin, chapped lips, headaches, and bone pain. Most of these side effects are temporary and resolve after treatment ends. Doctors can prescribe medications to manage nausea and pain, and provide advice on caring for skin and mouth during treatment.

Innovative Approaches in Clinical Trials

While standard treatment has achieved remarkable success, researchers continue to explore new ways to improve outcomes and reduce side effects through clinical trials. These studies test promising new therapies and treatment combinations that may become tomorrow’s standard care^[9].

One major area of investigation focuses on chemotherapy-free treatment approaches. Recent clinical trials have shown that combining ATRA with arsenic trioxide, without traditional chemotherapy, can be highly effective for patients with low-risk disease. This approach has the advantage of avoiding many of the side effects associated with chemotherapy, such as severe nausea, hair loss, and increased infection risk^[11].

Several large clinical trials conducted in Europe and the United States have demonstrated that ATRA plus arsenic trioxide combinations can achieve complete remission rates exceeding 90%, with event-free survival rates (meaning patients remain free of disease without serious complications) also above 90%^[2]. These impressive results have led some medical centers to adopt this approach as their preferred treatment for appropriate patients.

For patients whose disease has come back after initial treatment, or for those who did not respond to standard therapy (called refractory disease), clinical trials are testing different combinations and sequences of medications. Some studies are exploring whether adding gemtuzumab ozogamicin to standard regimens can improve outcomes, particularly for high-risk patients^[10].

Researchers are also investigating new formulations of existing medications to make treatment more convenient and accessible. For instance, clinical trials are testing oral (pill) forms of arsenic trioxide that patients could take at home, rather than requiring intravenous infusions in a clinic or hospital. One such preparation being studied is called realgar-Indigo naturalis formula, which combines oral arsenic with other traditional medicine components^[11].

These oral arsenic preparations have shown promising results in early-phase clinical trials. Phase II trials, which focus on determining whether a treatment is effective, have demonstrated that oral arsenic can achieve remission rates similar to intravenous arsenic while allowing patients more flexibility and reducing the need for frequent hospital visits. Phase III trials, which compare new treatments directly against current standard treatments in larger groups of patients, are ongoing in several countries including China and may expand to other regions.

Another innovative area of research involves studying the biological mechanisms that cause acute promyelocytic leukaemia cells to respond so well to ATRA and arsenic trioxide. By understanding exactly how these medications work at the molecular level, scientists hope to identify additional targets for new therapies. This research has revealed that the abnormal PML-RARα protein created by the genetic translocation in acute promyelocytic leukaemia cells is particularly vulnerable to these drugs, which explains why this type of leukaemia responds so much better to targeted therapy than other forms of acute myeloid leukaemia^[4].

Clinical trials are also focusing on ways to reduce early death during the induction phase of treatment. This remains a challenge, as some patients experience severe bleeding or complications before the treatment has time to work. Studies are testing whether starting treatment with certain medications immediately upon suspicion of acute promyelocytic leukaemia, even before confirmation through specialized laboratory tests, can reduce mortality. Additional trials are examining optimal doses and timing of supportive care measures, such as platelet transfusions and medications to support blood clotting.

Some research centers are investigating whether patients who achieve excellent responses to initial treatment might be able to shorten or even skip certain phases of therapy. For example, studies are evaluating whether patients who achieve very rapid remission with no detectable disease by sensitive molecular tests might be able to complete a shorter maintenance phase, potentially reducing long-term side effects and improving quality of life.

For patients interested in participating in clinical trials, eligibility typically depends on factors such as the phase of disease (newly diagnosed, relapsed, or refractory), prior treatments received, overall health status, heart and kidney function, and age. Clinical trials for acute promyelocytic leukaemia are being conducted at major cancer centers in the United States, Europe, and other regions around the world^[9].

Long-Term Outlook and Survivorship

The prognosis for patients with acute promyelocytic leukaemia has improved dramatically over recent decades. Current treatment approaches achieve 10-year survival rates of approximately 80-90%, a remarkable achievement considering this disease was almost universally fatal just a few decades ago^[4]. Most patients who complete treatment successfully can expect to live long, healthy lives.

Around 85 to 90% of individuals treated for acute promyelocytic leukaemia achieve complete remission, meaning no leukaemia cells can be detected in their blood or bone marrow^[7]. Among those who achieve remission, approximately 75% remain cancer-free for at least five years^[7]. Patients who maintain complete remission for at least three years have a very low chance of the disease returning.

Long-term survivorship care includes regular follow-up visits with the healthcare team, typically every few months initially, then less frequently as time passes. During these visits, doctors perform blood tests to monitor blood cell counts and check for any signs of disease recurrence. Some patients may also undergo periodic bone marrow examinations, especially in the first few years after treatment.

Survivors should be aware of potential late effects from treatment, which can include increased risk of developing other cancers later in life, particularly if they received chemotherapy or radiation. Regular health screenings, such as mammograms, colonoscopies, and skin examinations, become important parts of long-term care^[15]. Heart function may also need monitoring in patients who received certain chemotherapy drugs.

Many survivors experience emotional and psychological challenges during and after treatment. A diagnosis of cancer at a relatively young age—most patients are diagnosed in their 30s or 40s—can disrupt career plans, family life, and personal goals^[1]. Support from mental health professionals, social workers, and peer support groups can be valuable in helping patients and families cope with these challenges and adjust to life after cancer.

Most common treatment methods

• All-trans retinoic acid (ATRA)
  • A vitamin A-derived medication that helps immature leukaemia cells mature and develop normally rather than killing them directly
  • Forms the cornerstone of induction therapy for acute promyelocytic leukaemia
  • Usually given in combination with other medications for best results
  • Can cause side effects including dry skin, chapped lips, headaches, and bone pain
• Arsenic trioxide
  • A highly effective medication particularly suited for treating acute promyelocytic leukaemia
  • Works by targeting the abnormal PML-RARα protein created by the genetic mutation
  • Can be combined with ATRA to create a chemotherapy-free treatment approach for low-risk patients
  • Requires monitoring for heart rhythm changes through regular electrocardiograms
  • Oral formulations are being tested in clinical trials for easier administration
• Anthracycline chemotherapy
  • Includes drugs such as idarubicin and daunorubicin that stop cancer cells from multiplying
  • Often used in combination with ATRA for induction therapy, particularly in high-risk patients
  • May cause side effects including nausea, hair loss, mouth sores, and increased infection risk
  • First successfully used in acute promyelocytic leukaemia treatment in 1973
• Targeted therapy with gemtuzumab ozogamicin
  • An antibody-drug conjugate that delivers cancer-killing substances directly to leukaemia cells
  • Attaches to specific proteins on the surface of abnormal cells
  • May be added to standard regimens in certain patients to improve outcomes
• Supportive care measures
  • Platelet transfusions to control bleeding and prevent hemorrhage
  • Fresh frozen plasma and cryoprecipitate to replace missing clotting factors
  • Blood transfusions to treat anemia and improve oxygen delivery
  • Antibiotics and other medications to prevent and treat infections